University of Pittsburg Medical Center
Welcome,         Profile    Billing    Logout  
 47 Trials 
127 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Crofford, Leslie
FM-TIPS, NCT04683042: Fibromyalgia TENS in Physical Therapy Study (TIPS): an Embedded Pragmatic Clinical Trial

Active, not recruiting
3
450
US
Transcutaneous Electrical Nerve Stimulation (TENS) with PT, PT only
Kathleen Sluka
Fibromyalgia
03/25
03/25
ALKIVIA, NCT05523167 / 2021-001277-23: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants with Active Idiopathic Inflammatory Myopathy.

Recruiting
2/3
240
Europe, Canada, Japan, US, RoW
EFG PH20 SC, PBO
argenx, argenx BV
Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
12/26
02/27
ClearMEMory, NCT03527472: Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus

Recruiting
2
80
US
Memantine, Namenda, Placebo
Vanderbilt University Medical Center, Evergreen Therapeutics, Inc., The University of Texas Health Science Center, Houston, The Cleveland Clinic
Lupus Erythematosus, Systemic
06/26
12/26
Ragni, Margaret V
WOMAN, NCT04344860: Prevent Postpartum Hemorrhage in Women with Von Willebrand Disease: the VWD- Trial

Completed
3
20
US
Recombinant Von Willebrand factor, rVWF, Vonvendi, Tranexamic Acid Injection [Cyklokapron], TA, Cyclokapron
Nicoletta C Machin
Von Willebrand Diseases, Postpartum Hemorrhage
08/24
09/24
VWDMin, NCT02606045: Minimize Menorrhagia in Women With Von Willebrand Disease

Terminated
3
39
US
recombinant von Willebrand factor, vonicog alfa, Vonvendi, tranexamic acid, Lysteda®
Margaret Ragni, University of North Carolina, Duke University, National Heart, Lung, and Blood Institute (NHLBI)
Von Willebrand Diseases
04/22
08/22
NCT03734588: Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors

Completed
1/2
4
US
SPK-8016
Spark Therapeutics
Adeno-Associated Virus (AAV), Blood Coagulation Disorder, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, Factor VIII (FVIII), Factor VIII (FVIII) Deficiency, Factor VIII (FVIII) Gene, Factor VIII (FVIII) Protein, Genetic Diseases, Inborn, Genetic Diseases, X-Linked, Gene Therapy, Gene Transfer, Hematologic Diseases, Hemorrhagic Disorders, Recombinant, Vector, Inhibitors
10/20
01/23
NCT03003533: A Gene Transfer Study for Hemophilia A

Completed
1/2
25
Canada, US, RoW
SPK-8011
Spark Therapeutics, Inc.
Hemophilia A
12/23
12/23
NCT04770935: To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD)

Completed
1
6
Europe, US
efanesoctocog alfa (BIVV001)
Bioverativ, a Sanofi company
Von Willebrand's Disease (VWD)
12/22
12/22
B-Natural, NCT02502409: Natural History Study of Factor IX Treatment and Complications

Active, not recruiting
N/A
550
US
Standard care with blood and urine sample collection
Skane University Hospital, Indiana Hemophilia &Thrombosis Center, Inc., Bioverativ Therapeutics Inc., Swedish Orphan Biovitrum
Factor IX Deficiency
06/19
12/21
NCT04055051: ATHN 11: Liver Transplantation Outcomes Study

Completed
N/A
86
US
American Thrombosis and Hemostasis Network, BioMarin Pharmaceutical
Hemophilia A and B, Liver Transplantation
12/22
12/22
ATHN 9, NCT03853486: Severe VWD Natural History Study

Active, not recruiting
N/A
108
US
American Thrombosis and Hemostasis Network, Takeda
Von Willebrand Diseases
12/24
01/25
ATHN Transcends, NCT04398628: A Natural History Study of Non-Neoplastic Hematologic Disorders

Recruiting
N/A
3000
US
American Thrombosis and Hemostasis Network, Pfizer, Hemophilia of Georgia, Inc., Genentech, Inc., Hemab Therapeutics, CSL Behring, Sanofi, Novo Nordisk A/S
Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
06/35
12/35
Sciurba, Frank C
RELIANCE, NCT04069312: Roflumilast or Azithromycin to Prevent COPD Exacerbations

Recruiting
4
1250
US
Roflumilast, Daliresp, Azithromycin, Zithromax
Johns Hopkins University, Patient-Centered Outcomes Research Institute, University of Illinois at Chicago
Chronic Obstructive Pulmonary Disease Severe, Chronic Bronchitis
03/26
05/26
INHALE, NCT06135324: Impairments That Affect Correct Inhaler Use in COPD

Recruiting
N/A
500
US
COPD Foundation, Viatris Inc.
COPD
12/24
07/25
ZEVR, NCT04186546: Zephyr Valve Registry

Active, not recruiting
N/A
150
US
Zephyr Valve Procedure, Zephyr Endobronchial Valve, Endobronchial Valve, Bronchoscopic Lung Volume Reduction, BLVR
Pulmonx Corporation
Emphysema
12/24
12/26
DLP-LHC, NCT06177717: Deep Functional Phenotyping of the ALA Lung Health Cohort

Recruiting
N/A
1000
US
Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI), American Lung Association, University of Vermont
Lung Diseases
07/26
07/26
RheSolve, NCT04677465: Clinical Study of the RheOx Bronchial Rheoplasty System in Treating the Symptoms of Chronic Bronchitis

Active, not recruiting
N/A
270
Europe, US
RheOx Bronchial Rheoplasty, Sham Procedure
Gala Therapeutics, Inc.
Chronic Bronchitis
05/24
10/25
NCT04543461: American Lung Association (ALA) Lung Health Cohort

Recruiting
N/A
4000
US
Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI), American Lung Association, Stanford University
Lung Diseases
09/26
09/26
NCT06404047: RECOVER-ENERGIZE Platform Protocol

Recruiting
N/A
660
US
Personalized Cardiopulmonary Rehabilitation, Structured Pacing, Education, Usual Care
Duke University, National Heart, Lung, and Blood Institute (NHLBI)
Long COVID, Long Covid19, Long Covid-19
10/25
01/26
AIRFLOW-3, NCT03639051: Evaluation of the Safety and Efficacy of TLD in Patients with COPD

Active, not recruiting
N/A
464
Europe, US
Targeted Lung Denervation (TLD), TLD, TLD Therapy, Optimal Medical Care
Nuvaira, Inc.
COPD
10/24
09/28
NCT05204888: MyAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home

Recruiting
N/A
642
Canada, US
myAirvo3, Pulse oximeter
Temple University, Fisher and Paykel Healthcare
COPD
01/27
03/27
NCT00307281: Emphysema Research Registry and Biosample Repository

Recruiting
N/A
3000
US
University of Pittsburgh
Emphysema, Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
07/30
07/30
Criner, Gerard J
VIGOR, NCT05583188: Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC

Terminated
4
5
US
Aliya Pulsed Electric Fields (PEF) ablation, Nivolumab plus Platinum Doublet Chemotherapy, Carboplatinum, Cipsplatin, Pemetrexed, Gemcitabine, Paclitaxel, Standard of care neoadjuvant therapy, Vinorelbine, Surgical Resection
Galvanize Therapeutics, Inc.
NSCLC
02/24
03/24
RELIANCE, NCT04069312: Roflumilast or Azithromycin to Prevent COPD Exacerbations

Recruiting
4
1250
US
Roflumilast, Daliresp, Azithromycin, Zithromax
Johns Hopkins University, Patient-Centered Outcomes Research Institute, University of Illinois at Chicago
Chronic Obstructive Pulmonary Disease Severe, Chronic Bronchitis
03/26
05/26
BOSTON-2, NCT03656926 / 2018-003205-25: Efficacy + Safety of Liposome Cyclosporine a to Treat Bronchiolitis Obliterans Post Single Lung Transplant

Completed
3
220
Europe, US, RoW
Liposomal Cyclosporine A, L-CsA, Standard of Care, SoC
Zambon SpA, BREATH Therapeutics Inc.
Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
03/24
03/24
BOSTON-1, NCT03657342 / 2018-003204-39: Efficacy + Safety of Liposome Cyclosporine a to Treat Bronchiolitis Obliterans Post Single Lung Transplant

Completed
3
220
Europe, US, RoW
Liposomal Cyclosporine A, L-CsA, standard of care, SoC
Zambon SpA, BREATH Therapeutics Inc.
Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
04/24
04/24
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Data from MATINEE trial for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD
Hourglass Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD
Completed
3
806
Europe, Canada, US, RoW
Placebo, Mepolizumab
GlaxoSmithKline, PPD DEVELOPMENT, LP
Pulmonary Disease, Chronic Obstructive
08/24
08/24
RESOLUTE, NCT04053634 / 2019-001800-39: Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

Jan 2024 - Dec 2024: Data from RESOLUTE trial for COPD
Active, not recruiting
3
689
Europe, Canada, Japan, US, RoW
Benralizumab, Placebo
AstraZeneca
Chronic Obstructive Pulmonary Disease
08/25
08/25
PRECISIONS, NCT04300920: Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection () Trial

Active, not recruiting
3
202
US
N-acetyl cysteine, NAC, Placebo
Weill Medical College of Cornell University, University of Virginia, University of Michigan, Pulmonary Fibrosis Foundation, University of Washington, National Heart, Lung, and Blood Institute (NHLBI), Three Lakes Foundation
Idiopathic Pulmonary Fibrosis
02/26
02/26
CHILL, NCT04545424: Trial of Therapeutic Hypothermia in Patients With ARDS

Recruiting
2
340
US
Hypothermia, targeted temperature management, Neuromuscular Blocking Agents, Paralytics, Standard of care, Usual temperature managementl
University of Maryland, Baltimore, US Department of Veterans Affairs Cooperative Studies Program, KAI Research, United States Department of Defense
Respiratory Distress Syndrome, Adult
06/26
09/26
RXC007 0002, NCT05570058 / 2022-000498-15: Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis

Hourglass Jan 2024 - Mar 2024 : Q1'24 - Topline data from trial for IPF
Active, not recruiting
2
48
Europe, RoW
RXC007, Placebo
Redx Pharma Plc, Simbec-Orion Group
IPF, Fibrosis
06/24
01/25
NCT06317285: A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Recruiting
2
150
Europe, Canada, US, RoW
GSK3915393, Placebo
GlaxoSmithKline
Idiopathic Pulmonary Fibrosis
03/26
03/26
CONQUEST, NCT06195072: Platform Clinical Study for Conquering Scleroderma

Recruiting
2
400
US
Amlitelimab, BI 1015550, Placebo
Scleroderma Research Foundation, Inc., Sanofi, Boehringer Ingelheim
Interstitial Lung Disease Due to Systemic Disease, Scleroderma
11/26
11/26
NCT05032066: A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis

Jan 2024 - Dec 2024: Data from trial for diffuse cutaneous systemic sclerosis
Terminated
2
153
Europe, Canada, Japan, US, RoW
HZN-825, Placebo
Amgen
Idiopathic Pulmonary Fibrosis
07/24
01/25
SUSPIRE-1, NCT06533553: A Study to Assess the Effects of Dexpramipexole in Participants with Eosinophilic COPD

Recruiting
2
30
US
Dexpramipexole Dihydrochloride
Areteia Therapeutics
Chronic Obstructive Pulmonary Disease
04/25
06/25
STRIVE-IPF, NCT03286556: Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis

Completed
2
51
US
Autoantibody Reductive Therapy, Treatment as Usual (TAU), Antibiotics and steroids
University of Alabama at Birmingham, National Heart, Lung, and Blood Institute (NHLBI), Brigham and Women's Hospital, Temple University, University of Pittsburgh
Idiopathic Pulmonary Fibrosis, Acute Fatal Form
08/24
08/24
NCT05671835: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

Recruiting
2
75
US
TTI-101, Placebo
Tvardi Therapeutics, Incorporated
Idiopathic Pulmonary Fibrosis
03/25
07/25
DEPTH, NCT05382208: Doxycycline for Emphysema in People Living With HIV (The Trial)

Recruiting
2
250
US
Doxycycline, Placebo
Weill Medical College of Cornell University, National Heart, Lung, and Blood Institute (NHLBI), University of California, Los Angeles, University of Iowa, University of Michigan
Emphysema, HIV
02/27
02/27
NCT05571059: Oral Ifetroban in Patients with Idiopathic Pulmonary Fibrosis (IPF)

Recruiting
2
128
US
Ifetroban Sodium, ifetroban, Placebo
Cumberland Pharmaceuticals
Idiopathic Pulmonary Fibrosis
01/26
01/26
NCT05195918: Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients

Recruiting
1
50
US
EGCG 300 mg + Nintedanib, epigallocatechin-3-gallate + Ofev, EGCG 300 mg + Pirfenidone, epigallocatechin-3-gallate + Esbriet, Placebo 2 capsules + Nintedanib or Pirfenidone, Placebo + Ofev or Esbriet, EGCG 600 mg + Nintedanib, EGCG 600 mg + Pirfenidone, Placebo 4 capsules + Nintedanib or Pirfenidone
Hal Chapman, University of Michigan, Cornell University, Massachusetts General Hospital, Temple University, University of Washington, University of Virginia
Idiopathic Pulmonary Fibrosis
04/26
04/26
NCT01796392: Pulmonx Endobronchial Valves Used in Treatment of Emphysema (LIBERATE Study)

Completed
N/A
190
Europe, US, RoW
EBV, Optimal Medical Management
Pulmonx Corporation
Emphysema
09/17
04/23
NCT05182294: Tolerance and Acute Effects of a New HFNT Nasal Cannula

Completed
N/A
14
US
AIRVO 2, the new asymmetric nasal cannula, Conventional asymmetric nasal cannula
Temple University, Fisher and Paykel Healthcare
COPD Exacerbation Acute
12/22
01/23
RESCUE3, NCT03783884: A Protocol Comparing Temporary Transvenous Diaphragm Pacing to Standard of Care for Weaning From Mechanical Ventilation

Terminated
N/A
223
Europe, US
Lungpacer Diaphragm Pacing Therapy, Lungpacer DPTS, AeroPace System
Lungpacer Medical Inc.
Ventilator Induced Diaphragm Dysfunction
12/22
01/23
NCT06035120: An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients with Severe Emphysema

Recruiting
N/A
200
Europe, US, RoW
AeriSeal System
Pulmonx Corporation
Emphysema, Pulmonary, Emphysema or COPD
06/27
03/28
HFCWO, NCT04271969: Clinical Effectiveness Of High Frequency Chest Wall Oscillation () In A Bronchiectasis Population

Completed
N/A
25
US
SmartVest Airway Clearance System
Electromed, Inc., University of Alabama at Birmingham
Bronchiectasis
12/23
12/23
NCT05204875: Functional Lung Imaging in Patients With Respiratory Compromise Undergoing Endobronchial Valve Placement

Recruiting
N/A
10
US
X-ray Velocimetry
Temple University, Respiratory Compromise Institute
Emphysema
11/23
12/23
SPRAY-CB, NCT03893370: RejuvenAir® System Trial for COPD With Chronic Bronchitis

Active, not recruiting
N/A
210
Europe, US
RejuvenAir System, Sham Control Procedure
CSA Medical, Inc.
Chronic Bronchitis
05/25
09/26
RheSolve, NCT04677465: Clinical Study of the RheOx Bronchial Rheoplasty System in Treating the Symptoms of Chronic Bronchitis

Active, not recruiting
N/A
270
Europe, US
RheOx Bronchial Rheoplasty, Sham Procedure
Gala Therapeutics, Inc.
Chronic Bronchitis
05/24
10/25
NCT04543461: American Lung Association (ALA) Lung Health Cohort

Recruiting
N/A
4000
US
Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI), American Lung Association, Stanford University
Lung Diseases
09/26
09/26
SPIROMICS, NCT01969344: Study of COPD Subgroups and Biomarkers

Active, not recruiting
N/A
2981
US
University of North Carolina, Chapel Hill, National Heart, Lung, and Blood Institute (NHLBI), COPD Foundation, Columbia University, Johns Hopkins University, National Jewish Health, Temple University, University of Alabama at Birmingham, University of California, Los Angeles, University of California, San Francisco, University of Illinois at Chicago, University of Iowa, University of Michigan, University of Utah, Wake Forest University
COPD, Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
12/30
12/30
AIRFLOW-3, NCT03639051: Evaluation of the Safety and Efficacy of TLD in Patients with COPD

Active, not recruiting
N/A
464
Europe, US
Targeted Lung Denervation (TLD), TLD, TLD Therapy, Optimal Medical Care
Nuvaira, Inc.
COPD
10/24
09/28
NCT04302272 / 2006-002338-39: STRIVE Post-Market Registry Study

Recruiting
N/A
150
US
Spiration Valve System (SVS)
Olympus Corporation of the Americas
Emphysema
04/25
04/28
NCT05119556: Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease

Recruiting
N/A
768
US
Video Telehealth Pulmonary Rehabilitation
University of Alabama at Birmingham, National Heart, Lung, and Blood Institute (NHLBI)
Chronic Obstructive Pulmonary Disease
06/26
08/27
NCT04165564: DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers

Active, not recruiting
N/A
85
US
Institutional standard of care, Biosamples of airway and blood
Boston University, Johnson & Johnson, American College of Radiology Imaging Network
Pulmonary Disease
12/26
12/26
Courcoulas, Anita
TRIUMPH-3, NCT05882045: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Active, not recruiting
3
1800
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Cardiovascular Diseases
01/26
02/26
Teen-LABS, NCT00474318: Teen-Longitudinal Assessment of Bariatric Surgery () Adolescent Bariatrics: Assessing Health Benefits and Risk

Completed
N/A
250
US
Ann & Robert H Lurie Children's Hospital of Chicago, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Children's Hospital Medical Center, Cincinnati, University of Pittsburgh Medical Center, University of Alabama at Birmingham, Nationwide Children's Hospital, Baylor College of Medicine, Sanford Health, University of Colorado, Denver
Obesity
06/24
06/24
NCT02710370: Intestinal Metabolic Reprogramming As a Key Mechanism of Gastric Bypass in Humans

Active, not recruiting
N/A
46
US
University of Pittsburgh, Harvard University, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Obesity, Diabetes Mellitus, Type 2, Endocrine System Diseases, Glucose Metabolism Disorders, Metabolic Diseases
08/26
08/26
TRIABETES, NCT01047735: The - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes

Active, not recruiting
N/A
69
US
Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, LapBand, Lifestyle Weight Loss Intervention
University of Pittsburgh, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type 2 Diabetes Mellitus, Obesity
07/25
07/25
Morris, Alison
BoDI, NCT03572335: Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)

Completed
N/A
61
US
PFT's (pulmonary function testing), 6MWT (6 minute walk test)
University of Pittsburgh
HIV Infections, Pulmonary Disease
10/22
08/24
ENDALI, NCT05316727: Electronic Nicotine Delivery Devices and Potential Progression to Acute Lung Injury

Completed
N/A
101
US
University of Pittsburgh, National Heart, Lung, and Blood Institute (NHLBI)
Acute Lung Injury, Pulmonary Injury, Electronic Cigarette Use, Electronic Cigarette Related Lung Injury
12/24
12/24
RIFFT, NCT05502653: Relationship of Inflammation and Pulmonary Function to Fungal Translocation in HIV

Recruiting
N/A
100
US
University of Pittsburgh, National Heart, Lung, and Blood Institute (NHLBI)
HIV Infections, Inflammation, COPD
08/26
08/27
Seaman, Craig D
PRESent-6, NCT06568302: The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial

Recruiting
3
150
Europe, Canada, US, RoW
SerpinPC, Activated Protein C (APC) inhibitor
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor
11/28
11/28
AHAEmi, NCT05345197: Emicizumab in Patients With Acquired Hemophilia A

Recruiting
2
51
US
emicizumab, Hemlibra (R)
University of Washington, Genentech, Inc.
Acquired Hemophilia A
07/25
12/25
PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

Active, not recruiting
2
60
Europe, Canada, US, RoW
SerpinPC, Activated Protein C (APC) inhibitor
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia a, Hemophilia B
11/24
02/25
Toma, Catalin
PROGRESS CTO, NCT02061436: Prospective Global Registry for the Study of Chronic Total Occlusion Intervention

Recruiting
N/A
2000
Europe, Canada, US, RoW
Minneapolis Heart Institute Foundation
Coronary Artery Disease
01/24
01/24
FLASH, NCT03761173: FlowTriever All-Comer Registry for Patient Safety and Hemodynamics

Completed
N/A
1186
Europe, US
FlowTriever System, Anticoagulation Agents
Inari Medical
PE - Pulmonary Embolism, PE - Pulmonary Thromboembolism
09/24
09/24
PEERLESS, NCT05111613: The Study

Completed
N/A
692
Europe, US
Catheter-Directed Thrombolysis, FlowTriever System
Inari Medical
Pulmonary Embolism, Pulmonary Thrombo-embolism
03/24
04/24
CorCinch-HF, NCT04331769: Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present with Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF): the CORCINCH-HF Study

Recruiting
N/A
400
Europe, US, RoW
AccuCinch Ventricular Restoration System, Guideline-Directed Medical Therapy
Ancora Heart, Inc.
Heart Failure with Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy
12/26
12/30
NCT06055920: The PEERLESS II Study

Recruiting
N/A
1200
Europe, Canada, US
FlowTriever System, Anticoagulation Agents
Inari Medical
Pulmonary Embolism
07/26
07/26
Moghadam-Kia, Siamak
ALKIVIA+, NCT05979441: A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults with Active Idiopathic Inflammatory Myopathy

Enrolling by invitation
3
240
Europe, US, RoW
EFG PH20 SC
argenx
Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
09/27
09/27
ALKIVIA, NCT05523167 / 2021-001277-23: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants with Active Idiopathic Inflammatory Myopathy.

Recruiting
2/3
240
Europe, Canada, Japan, US, RoW
EFG PH20 SC, PBO
argenx, argenx BV
Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
12/26
02/27
Singh, Michael
C-TRACT, NCT03250247: Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The Trial)

Recruiting
N/A
250
US
Stents
Washington University School of Medicine, Ontario Clinical Oncology Group (OCOG), Massachusetts General Hospital, Saint Luke's Mid America Heart Institute
Deep Vein Thrombosis, Venous Stasis, Venous Insufficiency, Venous Leg Ulcer, Venous Reflux, Post Thrombotic Syndrome
01/26
04/26
SSB 11-02, NCT02777528: Evaluation of the GORE® TAG® Thoracic Branch Endoprosthesis (TBE Device) in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta (Zone 0/1)

Active, not recruiting
N/A
150
Japan, US
GORE® TAG® Thoracic Branch Endoprosthesis, Revascularization Procedure
W.L.Gore & Associates
Aortic Aneurysm, Thoracic, Aorta, Lesion
03/24
03/28
TREO PAS, NCT04697784: Post-Approval Study of the TREO Abdominal Stent-Graft System

Recruiting
N/A
300
US
TREO Abdominal Stent-Graft System
Bolton Medical
Abdominal Aortic Aneurysm
07/27
07/27
Nguyen, Minh-Hong
MARIO, NCT05178862 / 2022-000648-32: A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

Suspended
3
220
Europe, Canada, US, RoW
SCY-078, Ibrexafungerp, Fluconazole, Diflucan, Echinocandin, Caspofungin, Micafungin, Anidulafungin
Scynexis, Inc., SCYNEXIS, Inc.
Candidiasis, Invasive, Candidemia
06/24
08/24
NCT05715619: Safety and Efficacy of Oral Administration of the Phage Cocktail, VRELysin™, In Healthy and VRE-Colonized Subjects

Recruiting
1/2
80
US
VRELysin™, Placebo, Phosphate Buffered Saline
Intralytix, Inc.
Vancomycin-Resistant Enterococcal Colonization
03/25
03/25
Lingg, Theresa
PDP, NCT06181669: Pneumonia Direct Pilot

Recruiting
N/A
250
US
Pathogen and Host Directed testing, Respiratory Pathogen ID/AMR Enrichment Panel (Illumina), Metagenomic Next Generation Sequencing (Illumina), T2 Bacteria Panel (T2 Biosystems), T2 Resistance Panel (T2 Biosystems), Procalcitonin (Abbott), TriVerity host (Inflammatix), Host gene expression, FilmArray Pneumonia Panel (BioFire)
Duke University, National Institute of Allergy and Infectious Diseases (NIAID)
Pneumonia, Bacterial, Ventilator Associated Pneumonia
04/25
07/25
Law, Ryan
NCT06174805: AXIOS™ Gastroenterostomy for Gastric Outlet Obstruction IDE

Not yet recruiting
N/A
67
Europe, Canada, US, RoW
AXIOS(TM) Stent and Electrocautery Enhanced Delivery System
Boston Scientific Corporation
Gastric Outlet Obstruction
02/27
02/27
Myslinski, Maria
INFINITE-US, NCT04225806: Investigation of Femoropopliteal In Situ Valve Formation With the InterVene System -

Terminated
N/A
15
US
BlueLeaf® Endovenous Valve Formation System (BlueLeaf System)
Intervene, Inc.
Chronic Venous Insufficiency (CVI), Deep Vein Reflux
09/23
09/23
GREAT, NCT06321575: The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy ( Trial)

Recruiting
N/A
159
US
Golazo® Peripheral Atherectomy System (Golazo® Peripheral AS)
Avantec Vascular, Bright Research Partners, Yale Cardiovascular Research Group
Peripheral Arterial Disease
11/26
11/26
NCT05928221: Post Market Registry Study of the Philips QuickClear Mechanical Thrombectomy System

Recruiting
N/A
50
US
Thrombectomy, QuickClear Mechanical Thrombectomy system
Paul J. Gagne
Acute Deep Venous Thrombosis of Ileofemoral Vein
12/24
03/26
NCT04484220: Ellipsys Vascular Access System Post Market Surveillance (PS) Study

Active, not recruiting
N/A
142
US
Ellipsys Vascular Access System
Medtronic Endovascular
Renal Disease, End Stage, Kidney Disease, End-Stage, AV Fistula, Fistulas Arteriovenous
05/25
09/25
Burdin, Suzanne
NCT05206331: CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study

Recruiting
4
1855
US
contrast enhanced mammography, Iodinated Contrast Media (ICM)
Margarita Louise Zuley, National Cancer Institute (NCI)
Breast Cancer
11/26
11/27
NCT04484220: Ellipsys Vascular Access System Post Market Surveillance (PS) Study

Active, not recruiting
N/A
142
US
Ellipsys Vascular Access System
Medtronic Endovascular
Renal Disease, End Stage, Kidney Disease, End-Stage, AV Fistula, Fistulas Arteriovenous
05/25
09/25
Carlile, Robert M
RETHINK-1, NCT04994483: Simufilam 100 Mg for Mild-to-Moderate Alzheimer's Disease

Completed
3
804
Canada, US, RoW
Simufilam, PTI-125, Placebo
Cassava Sciences, Inc., Premier Research Group plc
Alzheimer Disease
10/24
10/24
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Remternetug, LY3372993, Placebo
Eli Lilly and Company
Alzheimer's Disease
04/29
10/30
NCT05397639 / 2021-003405-22: Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

Recruiting
3
375
Europe, US, RoW
Masupirdine 50 mg, SUVN-502, Masupirdine 100 mg, Placebo
Suven Life Sciences Limited, Suven Life Sciences Ltd
Agitation, Alzheimer's Type Dementia
01/25
01/25
REMODEL-1, NCT05147220 / 2020-005899-36: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
ALKIVIA, NCT05523167 / 2021-001277-23: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants with Active Idiopathic Inflammatory Myopathy.

Recruiting
2/3
240
Europe, Canada, Japan, US, RoW
EFG PH20 SC, PBO
argenx, argenx BV
Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
12/26
02/27
NCT06587828: A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients with Autoimmune Disease

Recruiting
N/A
300
US
Companion blood samples with procedure
TScan Therapeutics, Inc.
Autoimmune Diseases, Ulcerative Colitis, Multiple Sclerosis, Scleroderma, Ankylosing Spondylitis, Celiac Disease, Non-radiographic Axial Spondyloarthritis (nr-axSpA), Crohn's Disease, Birdshot Chorioretinitis
01/25
06/25
Applegate, Rachel
HEALEY ALS, NCT04297683: Platform Trial - Master Protocol

Active, not recruiting
2/3
1500
US
ABBV-CLS-7262, DNL343
Merit E. Cudkowicz, MD, Massachusetts General Hospital
Amyotrophic Lateral Sclerosis
07/25
04/26
Hughes, Kailey
CPAT-ISR, NCT05077254: COVID Protection After Transplant-Immunosuppression Reduction

Active, not recruiting
2
400
US
Pfizer-BioNTech COVID-19 Vaccine 2023-2024, mRNA COVID-19 vaccine, BNT162b2 mRNA COVID-19 vaccine, SARS-CoV-2 RNA vaccine, Comirnaty, Moderna COVID-19 Vaccine 2023-2024, Moderna COVID-19 vaccine, SARS-CoV-2 vaccine, Spikevax, SOC IS Regimen, Standard of Care transplant immunosuppression regimen, Immunosuppression (IS), mycophenolate mofetil (MMF) or equivalent, tacrolimus, SOC IS Reduction, Standard of Care (SOC) transplant immunosuppression regimen, Immunosuppression (IS) Reduction
National Institute of Allergy and Infectious Diseases (NIAID), PPD, Johns Hopkins University
Kidney Transplant Recipients, Liver Transplant Recipients
02/24
03/25
Coppieters, Sabine
ADDRESS, NCT04598451 / 2020-002915-23: A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)

Completed
3
222
Europe, Japan, US, RoW
efgartigimod PH20 SC, Placebo, prednisone
argenx
Pemphigus Vulgaris, Pemphigus Foliaceus
08/23
08/23
ADAPT NXT, NCT04980495 / 2021-002504-12: An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis

Active, not recruiting
3
69
Europe, Canada, US, RoW
Efgartigimod concentrate for solution for infusion 20 mg/mL, Efgartigimod IV
argenx
Generalized Myasthenia Gravis
08/23
05/26
ADVANCE SC, NCT04687072 / 2020-004032-21: A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

Completed
3
207
Europe, Japan, US, RoW
Efgartigimod PH20 SC, ARGX-113 PH20 SC, Placebo PH20 SC
argenx, argenx BV
Primary Immune Thrombocytopenia
10/23
10/23
NCT06298552: A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients with Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

Recruiting
3
110
Europe, Canada, US, RoW
Efgartigimod IV, Placebo IV
argenx
Generalized Myasthenia Gravis
07/25
07/27
ADDRESS+, NCT04598477 / 2020-002917-16: A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)

Terminated
3
183
Europe, Japan, US, RoW
efgartigimod PH20 SC, prednisone
argenx
Pemphigus Vulgaris, Pemphigus Foliaceus
03/24
03/24
BALLAD+, NCT05681481 / 2021-003063-10: A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants with Bullous Pemphigoid

Active, not recruiting
3
160
Europe, Japan, US, RoW
efgartigimod PH20 SC, Prednisone
argenx, argenx BV
Bullous Pemphigoid
01/26
03/26
ADVANCE SC+, NCT04812925 / 2020-004033-20: A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients with Primary Immune Thrombocytopenia

Active, not recruiting
3
173
Europe, Japan, US, RoW
efgartigimod PH20 SC, ARGX-113 PH20 SC
argenx
Primary Immune Thrombocytopenia
10/26
10/26
ALKIVIA+, NCT05979441: A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults with Active Idiopathic Inflammatory Myopathy

Enrolling by invitation
3
240
Europe, US, RoW
EFG PH20 SC
argenx
Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
09/27
09/27
 

Download Options